RMD.ASX HSN.ASX MGH.ASX XF1.ASX FPH.ASX

Market Roundup: ResMed Shines, Hansen Secures Major Deal, and Maas Group Proposes Buyback

ResMed Delivers Solid Q2 Results ResMed Inc. reported impressive financial results for the second quarter of fiscal year 2025. The company saw strong revenue growth in both its Sleep and Breathing Health and Residential Care Software segments. Profitability also improved, thanks to higher gross margins. ResMed continued to invest in research and development, expanding its product portfolio and driving innovation. The company maintained a healthy balance sheet and generated robust cash flow, allowing it to fund growth initiatives and return capital to shareholders.

Hansen Inks A$50M Agreement with Virgin Media Hansen Technologies has secured a significant five-year contract with VMO2, worth approximately A$50 million. Under the agreement, Hansen will license its cloud-native Suite for Communications, Technology & Media to VMO2, enabling the delivery of three platforms to enhance VMO2's capabilities. This strategic deal reaffirms Hansen's guidance for strong revenue and EBITDA growth in fiscal year 2025.

Maas Group Proposes Further Share Buyback Maas Group Holdings has announced a proposed further on-market share buyback of up to 10% of its issued ordinary share capital over the next 12 months. This follows the completion of the company's previous buyback program in January 2025. The move reflects the Maas Group Board's confidence in the business's performance and strong capital position.

Xref Shareholders to Vote on SEEK Acquisition Xref Limited is holding a Scheme Meeting for shareholders to vote on a proposed acquisition by SEEK Limited. Under the Scheme, SEEK will acquire 100% of Xref's issued shares for cash consideration of $0.218 per share, representing a 61% premium to Xref's undisturbed share price. The Independent Expert has concluded that the Scheme is fair and reasonable, and the Xref Board unanimously recommends that shareholders vote in favor.

Fisher & Paykel Braces for Impact of US Tariffs Fisher & Paykel Healthcare has announced that costs are forecast to increase due to new US tariffs on imports from Mexico, Canada, and China. The company's manufacturing operations and US revenue will be impacted, as a significant portion of its products are imported from Mexico and China. While the company does not anticipate a material impact on its net profit after tax for the 2025 financial year, the tariffs may delay the company's timeline to reach its gross margin target of 65%.